Metrion Biosciences appoints John Montana as Non-Executive Director Expansion of the Board of Directors will support the company’s further growth as an ion channels focused drug discovery CRO Cambridge, UK, 09 February 2021: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of John Montana, [...]
Metrion Biosciences and Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration • Ion channels represent a large but under-exploited class of drug targets beyond G protein-coupled receptors (GPCRs) • Collaboration combines Sosei Heptares’ leading structure-based drug design platform with Metrion Biosciences’ ion channel expertise • Joint [...]
Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaboration Ongoing collaboration extended for another 12 months and successfully progresses into late stage hit-to-lead optimisation phase Cambridge and London, UK, 18 January 2021: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent [...]
Two appointments in USA and Europe increase representation across key regions Partnership established with On Target Drug Discovery Service and Supply, Ltd. to represent Metrion in Japan Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has significantly enhanced its global business development capabilities, with additional resources [...]
Metrion Biosciences and International Scientific Consortium publish data and new recommendations for in vitro risk assessment of the cardiac safety of new medicines Part of the US FDA’s Comprehensive in vitro Proarrythmia Assay (CiPA) Initiative Cambridge, UK, 07 April 2020: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today [...]
Metrion Biosciences and LifeArc extend ion channel drug discovery collaboration to accelerate neuroscience-focused research Initial twelve month collaboration successfully identifies hit compounds and progresses into hit-to-lead optimisation phase Cambridge and London, UK, 03 December 2019: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical [...]
Metrion Biosciences Appoints Dr Andrew Southan as Chief Executive Officer Cambridge, UK, 08 April 2019: Metrion Biosciences (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Company’s Chief Operating Officer. Dr Southan joined [...]
Metrion Biosciences Closes Funding Round Includes investment from o2h Ventures Therapeutics Fund Funding to support expansion of ion channel screening capabilities and continued research into potential drugs for auto-immune diseases Cambridge, UK, 01 April 2019: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, announced today that it has completed [...]
Metrion Biosciences and LifeArc sign collaboration agreement for neuroscience-focused ion channel drug discovery Novel small molecule programme aims to address major unmet medical need in neuroscience Collaboration focused on specific potassium ion channel target Cambridge and London, UK, 29 January 2019: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and [...]
Metrion Biosciences makes senior appointments to strengthen its drug discovery leadership team Dr Edward Stevens appointed as Head of Drug Discovery, and Dr Andrew Lightfoot as Head of Medicinal Chemistry and Discovery Funding Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has made two senior appointments [...]
